GSDMD and metabolic dysfunction-associated steatotic liver disease: GSDMD has also been shown to target different levels of NAFLD such as fibrosis by activating stellate cells.19 This indicates that regulation of hepatocyte pryoptosis can lead to hepatoprotective effects in different NAFLD stages.